Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820070 | 0.89 | FERMT2 (0.47) | AAK1GAK | |
| SCHEMBL25820095 | 0.82 | HTR1A (0.51) | TRPV1PARP1ROCK2 | |
| SCHEMBL14550229 | 0.81 | CDK8 (0.45) | CCNCCDK8GAKIDO1PARP1 | |
| SCHEMBL25820130 | 0.81 | KDM4E (0.43) | TRPV1PARP1ROCK2 | |
| SCHEMBL25820094 | 0.78 | SLC22A12 (0.42) | TRPV1ROCK2 | |
| SCHEMBL25820108 | 0.78 | IP6K1 (0.43) | TRPV1ROCK2 | |
| SCHEMBL14147890 | 0.78 | LOXL2 (0.59) | CCNCCDK8AAK1GAKPARP1 | |
| SCHEMBL25820090 | 0.78 | TRPV1 (0.38) | CCNCCDK8GAKTRPV1ROCK2 | |
| SCHEMBL2494065 | 0.78 | LOXL2 (0.58) | AAK1 | |
| SCHEMBL25820092 | 0.77 | GABRA1 (0.34) | CCNCCDK8GAKTRPV1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | CCNC 821/4885CDK8 567/4885AAK1 1644/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | CCNC 491/4885CDK8 385/4885AAK1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.